Both remain classified as research compounds, and all published data comes from preclinical and animal studies rather than human clinical trials
GHK-Cu and Epithalon: Different Schedules for Different Goals GHK-Cu is typically administered once daily as part of skin or hair restoration protocols
What they found: No serious adverse events triggered by AOD-9604 The most frequent side effects: headache (~5 %), occasional fatigue, at the same frequency as placebo No changes in IGF-1 levels, glycemia, blood pressure, heart rate No signals of cardiovascular, hepatic or renal toxicity Safety profile comparable to placebo Why it matters: From a safety perspective, AOD-9604 is one of the safest peptides in the clinical registry
Neurochem Res
Other applications favor injection
We value your feedback on our articles, if you have a well-researched paper you would like to share with us please contact us